Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin

NCT04034524 · Unknown status

Last updated 2026-05-28

This study compares the time until the first major heart-related event (such as a heart attack or stroke) in adults with type 2 diabetes who start either GLP1 receptor agonists or basal insulin.

Status Unknown status The sponsor has not confirmed the status recently.

Type Observational

Participants 20,000 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2019-05 · est. completion 2020-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT04034524 ↗

Description as written by the study sponsor.

This study will compare hemoglobin a1c (HbA1c) and cardiovascular (CV) outcomes among patients with type 2 diabetes newly initiating a GLP1-receptor agonist or basal insulin.

Treatments tested

GLP-1 receptor agonist Drug

any GLP-1 receptor agonist (other than Saxenda or liraglutide 3.0mg)
Insulin also known as Basal Insulin Drug

glargine, detemir, neutral protamine Hagedorn (NPH), degludec

Main thing measured	Time until first composite CV event (myocardial infarction, stroke)
Sponsor	Brigham and Women's Hospital
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04034524 ↗